CLAIMS

1. Amino-terminally truncated MCP-2, lacking NH_2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity.

2. Amino-terminally truncated MCP-2 according to claim 1, lacking NH_2-terminal amino acids corresponding to amino acid residues 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity.

3. Amino-terminally truncated MCP-2 according to claim 1, having the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

4. Amino-terminally truncated MCP-2 according to one or more of the preceding claims, in a glycosylated form.

5. DNA molecules comprising the DNA sequences coding for the amino-terminally truncated MCP-2 of the invention according to one or more of the preceding claims, including nucleotide sequences substantially the same.

6. An expression vector which comprises the DNA molecule of any claim 5.

7. A host cell comprising the expression vector of claim 5.

8. A recombinant process for preparing any of the proteins from claim 1 to 4, comprising culturing in an appropriate culture medium the cells of claim 6.

9. A protein according to any of the claims from 1 to 4 for use as medicament.

10.Use of a protein according to any of the claims from 1 to 4, in the manufacture of a medicament for the therapy and/or diagnosis of diseases, in which an antagonistic activity of the chemokine effects is required.

11.Use according to claim 10, in the manufacture of a medicament for the treatment of inflammatory diseases, HIV-infection, angiogenisis and hematopoiesis-related diseases, and tumors.

12.A pharmaceutical composition comprising the protein according to any of the claims from 1 to 4 together with one or more pharmaceutically acceptable carriers and/or excipients.

Add D2

add B1